Fucis tablets 50 mg. №10

Description

Fucis 50 mg Composition
active substance: fluconazole

1 tablet contains fluconazole 50 mg;

excipients: lactose, microcrystalline cellulose, povidone K30, talc, magnesium stearate, sodium starch (type A), croscarmellose sodium.

Fucis 50 mg Dosage form
Pills.

Basic physical and chemical properties: white, round tablets with beveled edges with a break line on one side.

Fucis 50 mg Pharmacotherapeutic group
Antifungal agents for systemic use. Triazole derivatives. ATX code J02A C01.

Pharmacodynamics

Mechanism of action

Fluconazole, an antifungal agent of the triazole class, is a potent and selective inhibitor of fungal enzymes required for the synthesis of ergosterol. The primary mechanism of its action is the suppression of fungal 14 alpha-lanosterol demethylation, mediated by cytochrome P450, which is an integral step in the biosynthesis of fungal ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol by the membrane of the fungal cell and may be responsible for the antifungal activity of fluconazole. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems.

The use of fluconazole at a dose of 50 mg per day for 28 days does not affect the level of testosterone in the blood plasma in men or the level of endogenous steroids in women of reproductive age. Fluconazole at a dose of 200-400 mg per day does not show a clinically significant effect on the level of endogenous steroids or the response to ACTH stimulation in healthy male volunteers.

Pharmacological – Pharmacokinetics

According to the results of animal studies, there is a correlation between MIC and efficacy against experimental models of mycoses caused by Candida species. According to the results of clinical studies, there is a linear relationship between the AUC and the dose of fluconazole (approximately 1: 1). There is also a direct but insufficient relationship between AUC or dose and a positive clinical response to treatment for oral candidiasis and, to a lesser extent, candidemia. Similarly, the treatment of infections caused by strains for which fluconazole exhibits a high MIC is less satisfactory.

Indications
Treatment of such diseases in adults as:

cryptococcal meningitis;
coccidioidomycosis;
invasive candidiasis;
candidiasis of the mucous membranes, including candidiasis of the oropharynx and candidiasis of the esophagus, candiduria, chronic candidiasis of the skin and mucous membranes;
chronic atrophic candidiasis (candidiasis caused by the use of dentures) with the ineffectiveness of local dental hygiene products;
vaginal candidiasis, acute or recurrent when local therapy is inappropriate;
candidal balanitis when topical therapy is inappropriate;
dermatomycosis, including mycosis of the feet, mycosis of smooth skin, inguinal dermatomycosis; versicolor versicolor and candidal skin infections when systemic therapy is indicated,
dermatophytic onychomycosis, when the use of other drugs is inappropriate.
Prevention of such diseases in adults as:

Contraindications
Hypersensitivity to fluconazole, other azole compounds or to any of the excipients of the drug;
simultaneous use of fluconazole and terfenadine in patients who use fluconazole multiple times at doses of 400 mg / day and above;
the simultaneous use of fluconazole and other drugs that prolong the QT interval and are metabolized by the CYP3A4 enzyme (for example, cisapride, astemizole, pimozide, quinidine and erythromycin), see also the sections “Peculiarities of use” and “Interaction with other drugs and other types interactions “.